Ajanta Pharma reported a strong performance for the fourth quarter of FY26, with healthy year-on-year growth across revenue and profitability, supported by steady operational momentum.
Revenue from operations rose to ₹1,421.64 crore in Q4FY26, compared to ₹1,170.41 crore in the same quarter last year, marking a growth of approximately 21.5%. Including other income, total income increased to ₹1,483.07 crore from ₹1,188.52 crore, reflecting a 24.8% year-on-year rise.
On the cost side, total expenses climbed to ₹1,135.96 crore from ₹919.11 crore, registering a 23.6% increase. The rise in expenses was largely driven by higher employee benefits, other expenses, and material costs, indicating continued investment in operations and expansion.
Despite the increase in costs, profitability remained strong. Profit before tax stood at ₹347.11 crore, up from ₹269.41 crore in Q4FY25, translating into a robust growth of about 28.9%. This also led to a slight improvement in operating efficiency, with PBT margin rising to around 24.4% from 23.0% a year ago.
Net profit for the quarter came in at ₹266.70 crore, compared to ₹225.26 crore in the corresponding period last year, delivering a growth of roughly 18.4%. The relatively lower growth in net profit compared to PBT reflects higher tax outgo during the quarter.